JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

LEADING ARTICLE

    1. The experience of N. N. Blokhin Russian Cancer Research center (Moscow, Russian Federation)

    Keywords:Hepatocellular carcinoma,fibrolamellar carcinoma,chronic hepatitis B,chronic hepatitis C,cirrhosis,metabolic syndrome

    Abstract:Aims: To explore the spectrum of risk factors associated with hepatocellular cancer (HCC) in Russian Federation, their prognostic significance for overall survival (OS). Methods: retrospective trial of 380 HCC cases referred to Russian Cancer Research center n. a.N.N.Blokhin between 2005 and 2015. Results: We observed viral hepatitis in 221 (58,2%) pts; liver cirrhosis 203 (53,4%) pts. The most (n=94 from 105 pts) HBs+ cases were men, with cirrhosis in 64,8%. There was men’s (n=82) prevalence in HCV patients (n=114, 30%) also, mostly complicated with cirrhosis (n=100, 87,7%). We didn’t find any HCC-driven risk factors in 59 pts, including 28 pts with fibrolamellar carcinoma. There were 33 pts with alcohol intake as a risk factor. The main risk factors for 66 pts were signs of metabolic-associated diseases. HBV+ (p=0,041, HR=1,36), alcohol intake (р=0,0001, HR=1,75) and smoking (р=0.009, HR=1,52) were significant for OS. Diabetes mellitus, (p=0,03; HR=1,62), TNM stage (p<0,001; HR=1,42), АFP level (p=0,001) and male gender (p=0,024; HR=1,82) negatively correlates with OS worsening. Conclusions: Less than 60% of Russian HCC pts were HBV/HCV carriers or cirrhotic. HBV+ and HCV+ (27,6% and 30% pts); metabolic disorders (17,4%) and alcohol intake (8,7%) were predominant risk factors for HCС We didn’t observe significant OS difference between viral- and nonviral-associated HCC.

      1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
      2. Ferlay J, Soerjomataram I, Ervik M, eds, et al. GLOBOCAN2012: estimated cancer incidence and mortality prevalence worldwide in 2012. http:// globocan.iarc.fr/Default.aspx.
      3. Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133-1145.
      4. Давыдов М. И., Аксель Е. М.2014 г Статистика злокачественных новообразований в России и странах СНГ в 2012 г. УДК 616-006.04-036.22(47+57):31”2010”Д13.
      5. Каприн А. Д., Старинский В. В., Петрова Г. В. (ред). «Состояние онкологической помощи населению России в 2014 году» Москва; 2015 г. МНИОИ им. П. А. Герцена: филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» МЗ РФ Российский Центр информационных технологий и эпидемиологических исследований в области онкологии».
      6. Herbst DA, Reddy KR. Risk factors for hepatocellular carcinoma. Clin Liver Dis. 2012;1: 180-182.
      7. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991; 325:675-680.
      8. Sangiovanni A, Prati GM, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303-1310.
      9. Ioannou G, Splan M, Weiss N, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007;5:938-945.
      10. Патютко Ю. И. Сагайдак И. В. Чучуев Е. С. и соавт. Бюллетень медицинских Интернет-конференций. 2011; том 1, № 6-6.
      11. Oken M, Creech R, Tormey D, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
      12. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140:1182-1188 e1181.
      13. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60: 110-117.
      14. Uehara T, Ainslie G. R., Kutanzi K., et al. Molecular Mechanisms of Fibrosis-Associated Promotion of Liver Carcinogenesis. Toxicological Sciences 132(1), 53-63 2013.
      15. Cabibbo G., Maida M., Genco C., et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study W J Hepatol 2012 September 27; 4(9): 256-261.
      16. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: A tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980; 46:372-9.
      17. Honeyman JN, Simon EP, Robine N, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. (New York, NY). 2014; 343:1010-4.
      18. Mittal S., and El-Serag HB. Epidemiology of HCC: Consider the Population. J Clin Gastroenterol. 2013; 47(0): S2-S6.
      19. Yang JD, Kim WR, Coelho R, et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2011; 9:64-70.
      20. Hartwell HJ., Petrosky KY., Fox JG., et al. Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice. Proc. Natl Acad. Sci. USA (2014); 111, 11455-11460.
      21. Xu L., Gao H., Huang J., et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J of Gastroenterol and Hepatol 30 (2015) 1032-1039).
      22. Trichopoulos D, Bamia C, Lagiou P, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 2011; 103: 1686-1695/
      23. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer 2007; 97: 1005-1008.
      24. Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol 2014; 20: 9217-9228.
      25. Marrero J, Fontana R, Fu S, et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005;42:218-224.
      26. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
     


    Full text is published :
    Breder V.V. RISK FACTORS FOR HEPATOCELLULAR CANCER IN ONCOLOGY PRACTICE The experience of N. N. Blokhin Russian Cancer Research center. Experimental and Clinical Gastroenterology Journal. 2016;128(04):04-12
    Read & Download full text